We investigated the effects of
indacaterol on
cough and phlegm in patients with stable
chronic obstructive pulmonary disease (
COPD). We performed a meta-analysis with five randomized controlled trials (RCTs) of
indacaterol in stable
COPD patients. The symptom severity was defined using the St. George's Respiratory Questionnaire (SGRQ). We analyzed patients treated with 150 µg (n = 945) and 300 µg (n = 832) out of 3,325 patients who completed the SGRQ from five RCTs. After a 12-week treatment of 150 µg
indacaterol,
cough improvement was reported in 36.5% (316/866) of patients treated with
indacaterol vs. 32.2% (259/804) patients treated with placebo (Relative Ratio [RR], 1.13; 95% confidence interval [CI], 0.99-1.29). Phlegm improvement was reported in 31.0% (247/798) of patients treated with
indacaterol vs. 30.6% (225/736) of patients treated with placebo (RR, 1.01; 95% CI, 0.87-1.18).
Dyspnea improvement was reported in 39.5% (324/820) of patients treated with
indacaterol vs. 31.5% (237/753) patients treated with placebo (RR, 1.33; 95% CI, 1.03-1.71; P = 0.001, I(2) = 55.1%). Only
dyspnea improvement was significant compared to placebo even at the 300 µg
indacaterol dose. Compared to placebo, a 12-week treatment of the long-acting beta-agonist,
indacaterol might not have a significant effect on
cough or phlegm in stable
COPD.